An oral immunotherapy aimed at grass and pollen allergies has a benefit and safety profile that supports its approval, according...
Data for MK 7243 (sublingual allergy immunotherapy tablet), from Merck, in a Phase III study involving 1,501 adult and pediatric...
Merck announced that the FDA has approved Grastek (Timothy Grass Pollen Allergen Extract) Tablet for Sublingual Use [2800 Bioequivalent Allergy...
Stallergenes, announced that the FDA has approved Oralair, the first immunotherapy tablet to be available in the U.S. for the...
Merck Inc., announced that the Biologics License Application (BLA) for its investigational Timothy grass pollen (Phleum pratense) allergy immunotherapy tablet...
ALK has presented new data from the Grazax Asthma Prevention (GAP) trial with Grazax, ALK's allergy immunotherapy tablet against grass...
Stallergenes Greer announced that it has received approval from the FDA for the extension of the indication for Oralair (Sweet...
Soluprick SQ Grass Pollen is used in the diagnosis of specific IgE mediated allergic diseases.
Background: Moderate-to-severe allergic rhinitis (AR) may increase the risk of developing or worsening asthma, whereas treatment of AR with subcutaneously or sublingual allergen immunotherapy (SLIT) may slow this progression.
Merck Inc has announced that the FDA's Allergenic Products Committee has voted unanimously to recommend Grastek (sublingual Timothy Grass pollen...